Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Ten Patent Applications Related to RNAi

Title: Modulators of Angiogenesis
Number: 7,419,779
Filed: Sept. 2, 2003 PCT Filed: Sept. 2, 2003
Lead Inventor: James Lorens, Rigel Pharmaceuticals
The invention, the patent’s abstract states, relates to the “regulation of angiogenesis … [and] is directed to nucleic acids encoding angiogenesis regulatory proteins and nucleic acids … involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including … nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids, as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.”

Title: Methods and Kits for Mass Production of dsRNA
Number: 20080199915
Filed: May 2, 2003 PCT Filed: May 2, 2003
Lead Inventor: Eugene Makeyev, RNA-Line
“The invention relates to methods and kits for propagating target nucleic acid in the form of double-stranded RNA,” the patent application’s abstract states. “This invention relates in particular to a method for mass production of dsRNA.”
The method involves replicating a target nucleic acid by an RNA-dependent RNA polymerase in a living cell under conditions sufficient for template-directed RNA synthesis, the abstract adds.

Title: Methods for Delivery of Oligomeric Compounds
Number: 20080199960
Filed: May 13, 2005 PCT Filed: May 13, 2005
Lead Inventor: Rudolph Juliano, University of North Carolina
The invention, the patent application’s abstract states, “relates to the delivery of oligonucleotides to cells through the delivery of a composition or reagent comprising a hybridization complex comprising [an] antisense oligonucleotide which is modified to have a higher stability against degradation, and a … sense oligonucleotide [that] is prone to degradation.”
The invention further relates to “dendrimeric bioconjugates and compositions or reagents comprising them, wherein the bioconjugate comprises a conjugate moiety coupled to a dendrimeric structure and to their use to deliver oligomeric compounds including oligonucleotides or duplexes … to cells for modulation of gene expression,” the abstract adds.

Title: In Vivo Production of Small Interfering RNAs That Mediate Gene Silencing
Number: 20080200420
Filed: March 26, 2008
Lead Inventor: Phillip Zamore, University of Massachusetts Medical School
“The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs that selectively silence targeted genes … using the cell's own RNA interference pathway,” according to the patent application’s abstract. “By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially.”

Title: Invertebrate microRNAs
Number: 20080201801
Filed: Feb. 19, 2008
Lead Inventor: Edwards Allen, Monsanto
“This invention provides plants having resistance to invertebrate pests,” the patent application’s abstracts states. “More specifically, this invention discloses a non-natural transgenic plant cell expressing at least one invertebrate miRNA in planta for suppression of a target gene of an invertebrate pest or of a symbiont associated with the invertebrate pest. Also provided are recombinant DNA constructs for expression of at least one invertebrate miRNA in planta, a non-natural transgenic plant containing the non-natural transgenic plant cell of this invention, a non-natural transgenic plant grown from the non-natural transgenic plant cell of this invention, and non-natural transgenic seed produced by the non-natural transgenic plants, as well as commodity products produced from a non-natural transgenic plant cell, plant, or seed of this invention.”

Title: Methods and Compositions Relating to Gene Silencing
Number: 20080206835
Filed: Feb. 11, 2008
Lead Inventor: George Tzertzinis, New England Biolabs
The invention, the patent application’s abstract states, comprises “a method for obtaining a mixture of heterogeneous short double-stranded RNA molecules suitable for use in gene silencing by subjecting large double-stranded RNA to enzymatic cleavage under specified conditions. The resulting mixture consistently includes enhanced representation of fragments having a size of 21-22 nucleotides absent any fractionation step. The fragments contain sequences that collectively span the entire length of the large double-stranded RNA from which they are derived.
“Double-stranded RNA with sequences that individually represent segments of a target mRNA may be analyzed using the methods described herein to identify the most active subset of hsiRNA fragments or individual siRNA fragments for achieving gene silencing for any gene or transcribed sequences,” the abstract notes. “A method is additionally provided for preparing and cloning DNA encoding selected siRNA, hsiRNA mixtures or hairpin sequences to provide a continuous supply of a gene silencing reagent derived from any long double-stranded RNA.”

Title: Nucleic Acid Complex
Number: 20080206869
Filed: Jan. 23, 2006 PCT Filed: Jan. 23, 2006
Lead Inventor: Edvard Smith, Avaris
The invention, the patent application’s abstract states, “relates to modification of nucleic acids for specific delivery in vitro and in vivo. More specifically, the … invention relates to modification of RNA or DNA molecules in order to add functions in terms of delivery and specificity to RNA interference or antisense technology. A specific binding domain is incorporated into the nucleic acid to which a complementary nucleic acid, conjugated to a biologically active molecule, can hybridize.”

Title: Self-Processing RNA Expression Cassette
Number: 20080207539
Filed: Aug. 31, 2004 PCT Filed: Aug. 31, 2004
Lead Inventor: Patrick Arbuthnot, University of the Witwatersrand Medical School
“The invention provides a self-processing RNA expression cassette which includes at least one pair of processing units; an RNAi effecter sequence of predetermined length that regulates target gene expression [and] is flanked by said pair of processing units; and at least one pair of cognate ribozyme cis-cleavage target sites located 5' and 3' of the RNAi effecter sequence,” the patent application’s abstract states. “The self-processing RNA expression cassette is able to express in vivo and in vitro, and the RNAi effecter sequence includes at least one target recognition sequence derived from the hepatitis B virus X gene.”

Title: RNA Interference-Mediated Inhibition of Hepatitis C Virus Gene Expression Using Short Interfering Nucleic Acid
Number: 20080207542
Filed: Aug. 25, 2006
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
The invention, the patent application’s abstract states, “relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of gene expression and/or activity. The … invention is also directed to compounds, compositions, and methods relating to traits, diseases, and conditions that respond to the modulation of expression and/or activity of genes involved in gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases, and conditions.
“Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules … molecules capable of mediating RNA interference against gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle formulations of such small nucleic acid molecules,” the abstract adds. The invention “also relates to small nucleic acid molecules … that can inhibit the function of endogenous RNA molecules, such as endogenous microRNA … or that can inhibit the function of RISC to modulate gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs including cocktails of such small nucleic acid molecules and lipid nanoparticle formulations of such small nucleic acid molecules. Such small nucleic acid molecules are useful, for example, in providing compositions to prevent, inhibit, or reduce diseases, traits, and conditions that are associated with gene expression or activity in a subject or organism.”

Title: Methods and Compositions for Treating 5-Alpha-Reductase Type 1 and Type 2 Dependent Conditions
Number: 20080207545
Filed: Oct. 20, 2004 PCT Filed: Oct. 20, 2004
Lead Inventor: Glenn Hoke, Gene Logic
“The invention relates generally to the use of antisense oligonucleotides, small interfering RNA, and ribozymes to modulate expression of the human steroid 5-alpha-reductase gene and thereby modulate levels of dihydrotestosterone,” according to the patent application’s abstract. “Elevated levels of DHT are associated with various disorders including, but not limited to, skin diseases, hair loss, hirsuitism, and benign prostatic hyperplasia. The invention specifically relates to formulations of these antisense oligonucleotides, small interfering RNA, and ribozymes for administration to treat and prevent disorders.”

Title: siRNA Targeting 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase/IMP Cyclohydrolase
Number: 20080207884
Filed: July 24, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to ATIC.”

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.